OncoHost Showcases Innovative Insights in NSCLC Proteomics

Original content here

OncoHost Set to Present Groundbreaking Research on NSCLC

OncoHost, a pioneer in precision oncology and biomarker development, is making significant strides in the field of plasma proteomics. At the upcoming International Society for Liquid Biopsy Annual Congress, OncoHost will unveil two pioneering posters that emphasize the critical role of plasma proteomics in enhancing clinical decision-making and monitoring for patients with non-small cell lung cancer (NSCLC).

Poster 1: A New Perspective on Immunotherapy Monitoring

The first poster will present a comparative analysis focusing on plasma proteomic signatures in relation to circulating tumor DNA (ctDNA) for evaluating immunotherapy responses in advanced NSCLC. Led by Dr. Michal Harel, VP of Translational Medicine at OncoHost, this research highlights how careful profiling of plasma proteins—around 7,000 per sample—can illuminate patients' systemic responses to treatment.

Key Findings from the Study

The study uncovers three key proteomic signatures essential for understanding patient responses:

1. Availability of soluble PD-1/PD-L1 drug levels,
2. T-cell activation and immune interaction, and
3. Markers of lung tissue damage.

Significantly, the tissue-damage signature showed the ability to detect non-responders as far as 6.6 months ahead of standard imaging techniques. The ctDNA measures demonstrated a mere modest correlation, whereas proteomic analysis offered superior differentiation among various clinical response groups.

Dr. Harel's Insights

Dr. Harel remarked, "The results illustrate the comprehensive insights that plasma proteomics can provide, encompassing the intricate tumor-immune dynamics that ctDNA alone fails to capture. This represents a significant shift toward real-time treatment monitoring for immunotherapy patients."

Poster 2: Predicting Immunotherapy Outcomes with PROphetNSCLC

The second poster showcases the predictive power of OncoHost's proprietary PROphetNSCLC® test, which assesses immunotherapy benefits across various genomic profiles. Presented by Anna Manasherov, Director of Scientific Affairs, this research focuses on pre-treatment plasma samples taken from 308 NSCLC patients receiving immune checkpoint inhibitors.

Performance of PROphetNSCLC

The results highlighted that patients with a PROphet-POSITIVE result experienced significantly longer overall survival rates (HR=0.39, p<0.0001). This benefit was consistent across major mutation subgroups such as KRAS, STK11, TP53, and KEAP1. Moreover, the test's predictive capability remained robust, irrespective of mutational status or PD-L1 expression levels, reinforcing its reliability as a universal biomarker for forecasting immunotherapy response.

CEO Ofer Sharon's Comments

Ofer Sharon, MD, CEO of OncoHost, expressed enthusiasm about these advancements, stating, "The findings affirm the importance of PROphetNSCLC® as a mutation-agnostic tool that aids oncologists in selecting the most effective first-line treatments. Our research underscores how proteomics can transcend genomic limitations, offering clinical insights that are actionable and significant for patient care."

Learn More About OncoHost's Innovations

OncoHost, with its headquarters in Binyamina, Israel, and Cary, North Carolina, is committed to innovating precision medicine strategies to enhance patient outcomes. The company's flagship platform, PROphet®, employs a simple blood test to analyze proteomic patterns for guiding first-line immunotherapy decisions in NSCLC. This approach presents medical professionals with vital insights, aiming for marked improvements in overall patient survival rates.

Supported by a dedicated team and a robust clinical trial network across over 40 sites with 1,700 patients, OncoHost is well-positioned to advance the field of precision diagnostics and biomarker exploration to new heights.

‍